Chapter 73 Beifeng Pharmaceutical’s counterattack!
It is three parts of medicine that are poisonous.
Almost any drug will inevitably have cytotoxicity and will have a certain impact on liver and kidney function, whether it is more or less toxic.
This is why most drug instructions will prompt: People with liver and kidney dysfunction should use this drug with caution.
Other patients are fine. Hepatitis B patients have already damaged their livers and their liver function is unstable. Now you tell the subjects that our new drug is cytotoxic and hepatotoxic and may cause liver damage. .
Who dares to try the medicine?
So, three days after the second clinical phase of "Ecofovir" was launched, Tsingshan Pharmaceutical did not receive an application from a hepatitis B patient.
The matter quickly reached Zhang Yang’s ears, but Zhang Yang was not too worried.
After his assistance and improvement, although "Ecofovir" currently used in the second phase of clinical trials is still a semi-finished product, its side effects such as cytotoxicity and hepatotoxicity are no different from the complete product.
Most importantly,
After stimulating the cytotoxicity of "phenylpropanol", the current "Ecofovir" has reached a 25% cure rate. Especially for patients with a small amount of hepatitis B virus in their bodies, the cure rate can even reach 65%!
He believes that as long as the first batch of patients undergo the second phase clinical trial, once the results of the two-month trial are over, more hepatitis B patients will definitely participate in the trial with a cure rate of 25%!
At that time, one or two more drug improvements will be made to increase the cure rate to 75%, which will be enough to successfully enter the third phase of clinical trials and promote marketing.
The entire research and development process of "Acofovir" also looks more real.
As for where the first batch of Phase II clinical patients will come from?
After thinking for a moment, Zhang Yang decided to use money and subsidies.
"Any subject who participates in the second phase clinical trial of 'Ecofovir' will receive a subsidy of 20,000 yuan per person."
Sure enough,
The simplest way It is often the most effective. As soon as the news comes out, patients immediately come to inquire. Although there are still very few, it is much better than the previous few days.
While Zhang Yang was thinking of ways to advance the second phase of clinical trials, various pharmaceutical companies participating in the "Starlight Project" on the other side finally noticed that Qingshan Pharmaceutical passed the second phase of clinical trials.
Suzhou, General Manager Office of Hengrui Pharmaceuticals.
Although Hengrui has many businesses, General Manager Su Lin still asks about the progress of his "Starlight Project" every month.
"Wenping, how is the progress of our 'HR-006' project to cure hepatitis B?"
Su Wenping is still tall and thin. As Su Lin's absolute confidant, he is currently Specially responsible for the "Starlight Project" matters.
"Mr. Su, the progress of the 'HR-006' project is pretty good."
"In recent months, we have increased investment in R&D and transferred several experienced R&D personnel from other projects. The latest trial of 'HR-006' has increased the effective prevention rate of hepatitis B synthesis to 38.6%. Compared with clinical trials, It was 29.4% in the first period, which is a significant improvement.”
“Once the effective prevention rate can be increased to more than 50%, our hope of curing hepatitis B will greatly increase.”
Su Lin is satisfied! Nod.
As a person with a background in technology research and development, he is well aware of the difficulty of developing a new drug. It is very rare to increase the effective prevention rate by ten percentage points in a few months.
He couldn't help but feel more relaxed.
"What about other pharmaceutical companies? In particular, is there any new progress from Gilead?"
Su Wenping shook his head slightly.
“No.”
“Gilead’s data in the past two months are very ordinary, and they seem to have encountered a bottleneck; and other domestic pharmaceutical companies participating in the ‘Starlight Project’ have not Announce any major progress.”
Su Lin was not surprised. After all, drug research and development is almost done in years, and it is normal for there to be no results in a few months.
Just when Su Lin was about to end the inquiry, Su Wenping continued: "However, a week ago, Qingshan Pharmaceutical's drug code-named 'QS-001' successfully passed the first clinical phase and has now entered the second clinical phase."< br>
“Moreover, they More information about the drug 'QS-001' has been revealed. It is a drug with strong cytotoxicity. Even the ethics review board personally intervened and required them to make obvious cytotoxicity labels when promoting clinical trials. ..."
Qingshan Pharmaceutical?
Cytotoxicity?
Su Lin was slightly startled.
Actually, when Qingshan Pharmaceutical applied to join the "Starlight Project" a few months ago, he was indeed a little worried.
But as Qingshan Pharmaceutical’s project failed to pass the first clinical phase in the past few months, he gradually stopped paying so much attention to it.
Hearing the news from Qingshan Pharmaceutical at this time, he quickly took over the phase 1 trial data handed over by Su Wenping and looked at it, shaking his head slightly after a while.
"Cytotoxicity...Is this trying to kill the hepatitis B virus through cytotoxicity?"
"It's a very novel idea, but you can see that they revised the first clinical phase four times before passing it. It can be seen that they are probably trying, and they probably don't have a clear idea!"
"Well, they just entered In the second issue, you can follow up and see if there is any new progress!”
Su Wenping said yes without comment.
To be honest, he couldn’t understand Qingshan Pharmaceutical’s thinking.
But when he thought of Zhang Yang, he suddenly felt uneasy.
Based on his understanding of Tsingshan Pharmaceutical, Zhang Yang doesn't like to make blind decisions. Although the idea of cytotoxicity is very novel, could it be another problem-solving idea of Tsingshan Pharmaceutical?
He is not sure!
“We can’t listen to Mr. Su, we still have to find a way to get more information about Qingshan Pharmaceutical’s new drugs.”
Su Wenping secretly made a decision in his heart.
Hengrui Pharmaceuticals does not pay much attention to Tsingshan Pharmaceuticals, let alone other domestic pharmaceutical companies that participated in the "Starlight Plan". Some pharmaceutical companies did not even pay attention to Tsingshan Pharmaceuticals until the second week of clinical phase II. to this news.
Of course, there is one company that is an exception.
Beifeng Pharmaceutical General Manager Office.
“Boss, Zhang Yang and his team’s ‘QS-001’ project has passed the first clinical phase and has now been approved for the second clinical phase!”
“But it’s just as we imagined before. , their new drug does have a lot of Strong cytotoxicity, even the ethical review committee personally requested that it be labeled 'cytotoxic'"
"As far as I know, it is very difficult for them to recruit patients now. Do you think we should make more for them? Trouble?”
Ding Jian was sitting on the leather sofa, with a gloomy look in his eyes.
He has been having a hard time recently. The emergence of "Qingshan Ava" has completely reduced the generic drug "Eltrombopag" he invested in to a second-line drug. It can be said that this investment has become impossible. Recovered losses!
However, he is not discouraged. Currently, Beifeng Pharmaceutical still sells several star products, such as the generic drug "Tenofovir Alafenamide" for the treatment of hepatitis B, and the "Cyclosporine" for the treatment of anti-rejection. white"!
These two drugs alone are enough to support Beifeng Pharmaceutical’s profit source!
After recently hearing that Qingshan Pharmaceutical had joined the "Starlight Project", he immediately paid attention to this matter.
He is not worried that Qingshan Pharmaceutical can develop a drug to cure hepatitis B. He is thinking about how to create some trouble for Qingshan Pharmaceutical!
“Idiot, what’s the use of causing trouble for them now?”
“Didn’t you say last time that Qingshan Pharmaceutical accidentally caused several patients to become acutely ill during the first phase of clinical trials? Liver damage? Go and prepare the information, it will be of great use to you!”
……
PS: Thank you for the 500-coin reward!
(End of this chapter)